inclusion criteria: * patients ≥ 18 years old * patients with an increased risk of severe covid-19 belonging to one or more of the following groups : * age ≥ 50 years * body mass index ≥ 30 kg/m² * diabetes * hypertension * chronic renal failure (egfr \<60 ml/min) * chronic heart disease * asthma/chronic obstructive pumonary disease/cystic fibrosis * chronic liver disease * chronic neurological disease * solid organ transplant * bone marrow transplant * sickle cell anemia/ major thalassemias * active or currently treated or \<1 year diagnosed cancer * active or currently treated or \<1 year diagnosed malignant blood disease * immunosuppressive treatment observed for more than 1 month * laboratory confirmed sars-cov2 infection with mild covid-19, fulfilling all the following criteria: * positive sars-cov-2 rt-pcr nasal swab samples and * clinical symptoms and signs consistent with sars-cov2 infection including but not limited to, fever, upper respiratory tract infection signs, digestive signs, muscle pain, anosmia, dysgueusia...(1) * informed consent to participate to the trial * patients must be able and willing to comply with study visits and procedures

inclusion criteria: * patients ≥ 18 years old * patients with an increased risk of severe covid-19 belonging to one or more of the following groups : * age ≥ 50 years * body mass index ≥ 30 kg/m² * diabetes * hypertension * chronic renal failure (egfr \<60 ml/min) * chronic heart disease * asthma/chronic obstructive pumonary disease/cystic fibrosis * chronic liver disease * chronic neurological disease * solid organ transplant * bone marrow transplant * sickle cell anemia/ major thalassemias * active or currently treated or \<1 year diagnosed cancer * active or currently treated or \<1 year diagnosed malignant blood disease * immunosuppressive treatment observed for more than 1 month * laboratory confirmed sars-cov2 infection with mild covid-19, fulfilling all the following criteria: * positive sars-cov-2 rt-pcr nasal swab samples and * clinical symptoms and signs consistent with sars-cov2 infection including but not limited to, fever, upper respiratory tract infection signs, digestive signs, muscle pain, anosmia, dysgueusia...(1) * informed consent to participate to the trial * patients must be able and willing to comply with study visits and procedures

inclusion criteria: - patients ≥ 18 years old - patients with an increased risk of severe covid-19 belonging to one or more of the following groups : - age ≥ 50 years - body mass index ≥ 30 kg/m² - diabetes - hypertension - chronic renal failure (egfr <60 ml/min) - chronic heart disease - asthma/chronic obstructive pumonary disease/cystic fibrosis - chronic liver disease - chronic neurological disease - solid organ transplant - bone marrow transplant - sickle cell anemia/ major thalassemias - active or currently treated or <1 year diagnosed cancer - active or currently treated or <1 year diagnosed malignant blood disease - immunosuppressive treatment observed for more than 1 month - laboratory confirmed sars-cov2 infection with mild covid-19, fulfilling all the following criteria: - positive sars-cov-2 rt-pcr nasal swab samples and - clinical symptoms and signs consistent with sars-cov2 infection including but not limited to, fever, upper respiratory tract infection signs, digestive signs, muscle pain, anosmia, dysgueusia…(1) - informed consent to participate to the trial - patients must be able and willing to comply with study visits and procedures

inclusion criteria: - patients ≥ 18 years old - patients with an increased risk of severe covid-19 belonging to one or more of the following groups : - age ≥ 50 years - body mass index ≥ 30 kg/m² - diabetes - hypertension - chronic renal failure (egfr <60 ml/min) - chronic heart disease - asthma/chronic obstructive pumonary disease/cystic fibrosis - chronic liver disease - chronic neurological disease - solid organ transplant - bone marrow transplant - sickle cell anemia/ major thalassemias - active or currently treated or <1 year diagnosed cancer - active or currently treated or <1 year diagnosed malignant blood disease - immunosuppressive treatment observed for more than 1 month - laboratory confirmed sars-cov2 infection with mild covid-19, fulfilling all the following criteria: - positive sars-cov-2 rt-pcr nasal swab samples and - clinical symptoms and signs consistent with sars-cov2 infection including but not limited to, fever, upper respiratory tract infection signs, digestive signs, muscle pain, anosmia, dysgueusia…(1) - informed consent to participate to the trial - patients must be able and willing to comply with study visits and procedures